Cholinergic modulation of spontaneous hypothalamic-pituitary-adrenal activity and its circadian variation in man

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 8, 1996, Pages 2902-2907

  Llorente, Ignacio ^b   Lizcano, Fernando ^b   Alvarez, Rosa ^b   Diez, Nieves ^b   Sopena, Marcos ^b   Gil, María J ^a   Salvador, Javier ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CORTICOTROPIN; GROWTH HORMONE; HYDROCORTISONE; MUSCARINIC M1 RECEPTOR; PIRENZEPINE; PLACEBO; PYRIDOSTIGMINE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; GROWTH HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

ADRENOCORTICOTROPIC HORMONE; ADULT; CHOLINESTERASE INHIBITORS; CIRCADIAN RHYTHM; DRUG COMBINATIONS; GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MUSCARINE; PARASYMPATHETIC NERVOUS SYSTEM; PIRENZEPINE; PITUITARY-ADRENAL SYSTEM; PYRIDOSTIGMINE BROMIDE;

EID: 0029835171     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.8.2902     Document Type: Article

References (23)

1. Naumenko EV. 1967 Role of adrenergic and cholinergic structures in the control of the pituitary-adrenal system. Endocrinology. 80:69-76.
2. Hedge GA, Smelik PG. 1968 Corticotropin release: inhibition by intrahypothalamic implantation of atropine. Science. 159:891-892.
3. Jones MT, Millhouse EW. 1977 Neurotransmitter regulation of corticotropinreleasing factor in vitro. Ann NY Acad Sci. 297:536-560.
4. Buckingham JC, Hodges JR. 1979 Hypothalamic receptors influencing the secretion of Corticotropin releasing hormone in the rat. J Physiol. 290:421-431.
5. Calogero AE, Kamilaris TC, Gomez MT, et al. 1989 The muscarinic cholinergic agonist arecoline stimulates the rat hypothalamic-pituitary-adrenal axis through a centrally-mediated corticotropin-releasing hormone-dependent mechanism. Endocrinology. 125:2445-2453.
6. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL. 1980 Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma β-endorphin and Cortisol. Science. 209:1545-1546.
7. Risch SC, Kalin NH, Janowsky DS, Cohen RM, Pickar D, Murphy DL. 1983 Co-release of ACTH and β-endorphin immunoreactivity in human subjects in response to central cholinergic stimulation. Science. 222:77.
8. Freeman E, Touzel R, Grossman A, Besser M, Ross R. 1990 Pyridostigmine, an acetylcholinesterase inhibitor, stimulates growth hormone release, but has no effect on basal thyrotrophin or adrenocorticotrophin levels or the thyrotrophin response to thyrotrophin-releasing hormone. J Neuroendocrinol. 2:429-432.
9. Ghigo E, Arvat MR, Valette E, et al. 1990 Further evidence against a stimulatory role of the cholinergic system on the hypothalamic pituitary adrenal axis in man. Neuroendocrinol Lett. 2:12-16.
10. Raskind MA, Peskind ER, Veith RC, Wilkinson CW, Federighi D, Dorsa DM. 1990 Differential effects of aging on neuroendocrine responses to physostigmine in normal men. J Clin Endocrinol Metab. 70:1420-1425.
11. Murialdo G, Fonzi S, Torre F, et al. 1993 Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia. Neuropsychobiology. 28:177-183.
12. Chrousos GP, Gold PW. 1992 The concept of stress and stress system disorders. JAMA. 267:1244-1252.
13. Davis KL, Hollister LE, Overall J, Johnson A, Train K. 1976 physostigmine effects on cognition and affect in normal subjects. Psychopharmacology. 51:23-27.
14. Lewis DA, Sherman BM, Kathol RG. 1984 Analysis of the specificity of physostigmine stimulation of adrenocorticotropin in man. J Clin Endocrinol Metab. 58:570-573.
15. Dodt C, Hansen K, Uthgenannt D, Born J, Fehm HL. 1994 Cholinergic porentiation of the meal-related rise in ACTH and cortisol concentrations in men. Exp Clin Endocrinol. 102:460-466.
16. Castro RC, Vieira JGH, Chacra AR, Besser GM, Grossman AB, Lengyel AMJ. 1990 Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects. Acta Endocrinol (Copenh). 122:385-390.
17. Evans PJ, Dieguez C, Rees LH, Hall R, Scanlon MF. 1986 The effect of cholinergic blockade on the ACTH, β-endorphin and cortisol responses to insulin-induced hypoglycaemia. Clin Endocrinol (Oxf). 24:687-691.
18. Locatelli V, Torsello A, Redaelli M, Ghigo E, Massara F, Muller EE. 1986 Cholinergic agonist and antagonist drugs modulate[ ] the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. J Endocrinol. 111:271-278.
19. Ghigo E, Arvat E, Mazza E, et al. 1990 Failure of pyridostigmine to increase both basal and GHRH-induced GH secretion in the night. Acta Endocrinol (Copenh). 122:37-40.
20. Hammer R, Koss FW. 1979 The pharmacokinetic profile of pirenzepine. Scand J Gastroenterol. 57(Suppl):1-6.
21. Calogero AE, Gallucci WT, Bernardini R, Saoutis C, Gold PW, Chrousos GP. 1988 Effect of cholinergic agonists and antagonists on rat hypothalamic corticotropin-releasing hormone secretion in vitro. Neuroendocrinology. 47:303-308.
22. Michels KM, Meeker RB, Hayward JN. 1991 Muscarinic cholinergic control of vasopressin secretion from the acute hypothalamoneurohypophysial explant. Neuroendocrinology. 54:219-226.
23. Jones CT, Edwards AV. 1991 Muscarinic adrenal responses to acetylcholine in conscious calves. J Physiol. 444:605-614.